215 related articles for article (PubMed ID: 37482560)
1. Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Recourt K; de Boer P; van der Ark P; Benes H; van Gerven JMA; Ceusters M; van Nueten L; Drevets WC; Bhatacharya A; Browning M; Jacobs GE
Transl Psychiatry; 2023 Jul; 13(1):266. PubMed ID: 37482560
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K; van der Aart J; Jacobs G; de Kam M; Drevets W; van Nueten L; Kanhai K; Siebenga P; Zuiker R; Ravenstijn P; Timmers M; van Gerven J; de Boer P
J Psychopharmacol; 2020 Sep; 34(9):1030-1042. PubMed ID: 32248747
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
[TBL] [Abstract][Full Text] [Related]
7.
Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
[TBL] [Abstract][Full Text] [Related]
8. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
Transl Psychiatry; 2019 Sep; 9(1):216. PubMed ID: 31481683
[TBL] [Abstract][Full Text] [Related]
9. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors.
Yue N; Huang H; Zhu X; Han Q; Wang Y; Li B; Liu Q; Wu G; Zhang Y; Yu J
J Neuroinflammation; 2017 May; 14(1):102. PubMed ID: 28486969
[TBL] [Abstract][Full Text] [Related]
10. Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.
Nakonezny PA; Carmody TJ; Morris DW; Kurian BT; Trivedi MH
Int Clin Psychopharmacol; 2010 Nov; 25(6):328-33. PubMed ID: 20805756
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression.
Kent JM; Daly E; Kezic I; Lane R; Lim P; De Smedt H; De Boer P; Van Nueten L; Drevets WC; Ceusters M
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jun; 67():66-73. PubMed ID: 26804646
[TBL] [Abstract][Full Text] [Related]
12. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder.
Bonaventure P; Dugovic C; Kramer M; De Boer P; Singh J; Wilson S; Bertelsen K; Di J; Shelton J; Aluisio L; Dvorak L; Fraser I; Lord B; Nepomuceno D; Ahnaou A; Drinkenburg W; Chai W; Dvorak C; Sands S; Carruthers N; Lovenberg TW
J Pharmacol Exp Ther; 2012 Aug; 342(2):429-40. PubMed ID: 22570363
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1
Ruiz-Ruiz C; García-Magro N; Negredo P; Avendaño C; Bhattacharya A; Ceusters M; García AG
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174532
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
[TBL] [Abstract][Full Text] [Related]
15. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
Trivedi MH; Rush AJ; Ibrahim HM; Carmody TJ; Biggs MM; Suppes T; Crismon ML; Shores-Wilson K; Toprac MG; Dennehy EB; Witte B; Kashner TM
Psychol Med; 2004 Jan; 34(1):73-82. PubMed ID: 14971628
[TBL] [Abstract][Full Text] [Related]
16. Electroacupuncture Relieves Nerve Injury-Induced Pain Hypersensitivity via the Inhibition of Spinal P2X7 Receptor-Positive Microglia.
Xu J; Chen XM; Zheng BJ; Wang XR
Anesth Analg; 2016 Mar; 122(3):882-892. PubMed ID: 26599792
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant effects of acute sleep deprivation are reduced in highly controlled environments.
Goldschmied JR; Boland E; Palermo E; Barilla H; Dinges DF; Detre JA; Basner M; Sheline YI; Rao H; Gehrman P
J Affect Disord; 2023 Nov; 340():412-419. PubMed ID: 37553017
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates.
Ory D; Celen S; Gijsbers R; Van Den Haute C; Postnov A; Koole M; Vandeputte C; Andrés JI; Alcazar J; De Angelis M; Langlois X; Bhattacharya A; Schmidt M; Letavic MA; Vanduffel W; Van Laere K; Verbruggen A; Debyser Z; Bormans G
J Nucl Med; 2016 Sep; 57(9):1436-41. PubMed ID: 27199364
[TBL] [Abstract][Full Text] [Related]
19. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
[TBL] [Abstract][Full Text] [Related]
20. P2X
Yin J; Wang Y; Hu H; Li X; Xue M; Cheng W; Wang Y; Li X; Yang N; Shi Y; Yan S
J Cell Mol Med; 2017 Nov; 21(11):2695-2710. PubMed ID: 28470940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
